Food Allergy Market Forecast 2034: Companies by DelveInsight : Stay Ahead in Pharma with DelveInsight’s Competitive Intelligence Services

DelveInsight's Food Allergy Market Insights report offers a comprehensive view of current treatments, emerging drugs, market shares, and forecasted market size from 2020 to 2034 across the 7MM (United States, EU-4, UK, and Japan). The market is set to evolve with therapies like Omalizumab (monotherapy and adjunct to Multi-Allergen OIT), Ligelizumab (Novartis), CA002 (Camallergy), and VE416 (Vedanta Biosciences).

Request for sample report @ https://www.delveinsight.com/report-store/food-allergy-market-insights

Key Takeaways from the Food Allergy Market Report

The food allergy market in the 7MM is projected to grow at a steady CAGR through 2034, reaching ~USD 1,648 million in 2023.
Leading companies include Aimmune Therapeutics, Novartis, DBV Technologies, InnoUp Farma, COUR Pharma, Vedanta Biosciences, Regeneron, Genentech, and Camallergy.
Key therapies: INP20, CNP-201, Viaskin Peanut/DBV712, CA002, Omalizumab, Ligelizumab, AR201, Dupixent, Viaskin Milk, ADP101, IgGenix.
Total prevalent cases in EU4 and UK: ~16.9 million in 2023.
March 2025: Roche's OUtMATCH study shows Xolair (omalizumab) outperforms multi-allergen OIT in head-to-head trials for food allergies, with fewer side effects.
March 2025: Celltrion's FDA-approved OMLYCLO (omalizumab biosimilar) for asthma, CRSwNP, food allergies, and CSU.
March 2025: FDA approves ARS Pharma's neffy (epinephrine nasal spray) for anaphylaxis in children 4+ years (15-<30 kg), first major innovation in 35 years.
March 2024: Novartis initiates long-term extension study for Ligelizumab in food allergy.
January 2024: DBV Technologies launches Phase 3 study for DBV712 in 4-7-year-old peanut-allergic children.

Discover which therapies are expected to grab the food allergy market share @ Food Allergy Market Report

Food Allergy Overview

Food allergies trigger immune responses to specific foods, often proteins, causing symptoms from mild (itching, swelling) to severe (anaphylaxis). Genetic factors like IL-12 receptor b1 variations increase risk. Diagnostics include skin prick tests, DBPCFC, and APT. In February 2024, FDA approved Xolair (omalizumab) for IgE-mediated food allergies in patients 1+ years, based on OUtMATCH trial data.

Food Allergy Epidemiology Segmentation

Epidemiology covers historical and forecasted trends (2019-2032) in the 7MM, segmented by total prevalent cases, age-specific, and etiology-specific cases.

Download the report to understand which factors are driving food allergy epidemiology trends @ Food Allergy Epidemiological Insights

Food Allergy Treatment Market

Standard treatment: Strict allergen avoidance, plus antihistamines, epinephrine injections, and immunotherapies. Epinephrine is first-line for anaphylaxis. FDA approved Palforzia (AR101) in 2020 for peanut allergy desensitization in ages 4-17. Patients should carry auto-injectors like EpiPen.

Learn more about the FDA-approved drugs for food allergy @ Drugs for Food Allergy Treatment

Food Allergy Emerging Drugs and Key Companies

Companies like Novartis (Ligelizumab), NIAID/Genentech (Omalizumab), Regeneron (Dupilumab), and Alladapt (ADP101) are advancing therapies. Omalizumab trials aim to enable allergen consumption without symptoms. Ligelizumab targets IgE with higher affinity than omalizumab. Pipeline includes Vancomycin + VE416 (Vedanta), DBV712 (DBV), Remibrutinib (Novartis), PVX-108 (Aravax), Peanut SLIT-tablet (ALK-Abello), and VLP Peanut (Allergy Therapeutics). These could shift management from avoidance to tolerance.

Below is a carefully filtered landscape (Japan, South Korea, Taiwan only) of companies that themselves sponsor or co-sponsor interventional clinical trials in food allergy (peanut, milk, egg, multi-food etc.) across Phase 1–Phase 3. I excluded: trials run only by universities/hospitals without industry sponsorship, non-Asian companies merely running trials in Asia, products only marketed in allergy but without an interventional food-allergy clinical trial program. Because the food-allergy drug pipeline is still very small globally, the list is shorter than oncology/immunology — and almost entirely immunotherapy-based rather than classic small molecules.

JAPAN Astellas Pharma Inc. (Japan) Therapeutic area: Peanut allergy (desensitization immunotherapy) Headquarters: Tokyo, Japan Drug Candidate ASP0892 (formerly JRC-Vax / DNA vaccine platform) Item Details Trial ID NCT03755713 Clinical Phase Phase 1 (completed), early Phase 2 development reported Indication Peanut allergy Modality DNA immunotherapy vaccine MOA Plasmid DNA encoding peanut allergens designed to induce immune tolerance and shift immune response away from IgE-mediated hypersensitivity (Th2 → Th1/Treg skewing) Mechanism Uses DNA vaccine-based allergen immunotherapy. Intended to retrain immune system and suppress allergen-specific IgE reaction (mast-cell activation). Clinical / Regulatory Updates The FDA granted Fast Track designation for the peanut allergy therapeutic vaccine. The program began as a safety and immune-response Phase 1 study in peanut-allergic adults. Developed from an Immunomic Therapeutics platform licensed by Astellas. Key Significance This is one of the only non-oral immunotherapy approaches in food allergy being clinically tested in humans and represents a vaccine-style cure strategy rather than exposure-based desensitization.
SOUTH KOREA South Korea has many allergy biologics companies — but very few are sponsoring food-allergy interventional trials yet. However, one emerging microbiome-based therapeutic program is notable. Genome & Company (Korea) Headquarters: Pangyo, South Korea Focus: Microbiome immunotherapies Drug Candidate GEN-001 (microbiome therapeutic / MTT platform derivative programs) Item Details Trial ID NCT05695261 Clinical Phase Phase 2 Indication Peanut allergy Modality Microbiome therapy (oral microbial transplantation therapy, encapsulated) MOA Restores gut microbiota composition → induces immune tolerance via T-regulatory cell expansion and IgE suppression Mechanism Gut microbiome imbalance is strongly linked to allergic sensitization. Therapy aims to: restore Clostridia-rich microbial populations reduce Th2 cytokines promote immune tolerance. Clinical Updates Phase 2 study evaluates safety and tolerability of oral encapsulated fecal microbial transplantation therapy in peanut allergy patients. Importance This represents a next-generation disease-modifying approach (immune tolerance induction rather than desensitization).
TAIWAN Taiwan historically played a major scientific role in IgE-allergy therapeutics (e.g., anti-IgE antibodies), and new companies are beginning to move into clinical development. Immunwork Inc. (Taiwan) Headquarters: Taipei / Academia-Sinica spin-out Scientific founder: Dr. Tse-Wen Chang (co-inventor of anti-IgE therapies) Drug Candidate IMM-based anti-IgE monoclonal antibody programs (next-generation Xolair-like antibodies) Item Details Clinical Phase Early clinical (Phase 1 readiness / regional studies) Indication IgE-mediated allergic diseases including food allergy MOA Neutralizes circulating IgE and prevents FcεRI receptor activation on mast cells and basophils Mechanism Blocks IgE-allergen complex formation Prevents mast-cell degranulation Stops anaphylaxis cascade Scientific Background Anti-IgE therapy originated from research that led to omalizumab (Xolair) development. Early anti-IgE antibody research included studies in peanut allergy populations. Relevance to Food Allergy Anti-IgE therapy is now widely used as: adjunct to oral immunotherapy standalone prevention of severe reactions anaphylaxis-reduction therapy
HONG-KONG/TAIWAN-LINKED INDUSTRIAL PROGRAM (IMPORTANT) Although run through academic centers, one Asian biotech-supported immunotherapy program is clinically important because it is being commercially developed in Asia. Chinese University of Hong Kong + Industry partners (regional biotech backing) Program: PPOIT (Probiotic + Peanut Oral Immunotherapy) Item Details Trial Type Randomized controlled clinical trial Clinical Phase Phase 2-like interventional Mechanism Oral immunotherapy + probiotic immunomodulation MOA Controlled peanut exposure + microbiome immune tolerance Study uses gradual peanut dosing and probiotic to induce long-term tolerance over 18 months.

What You Should Notice (Market Insight) Food allergy pipelines differ from most therapeutic markets: 1. Asia is not focused on small molecules Nearly every program uses: immunotherapy vaccines antibodies microbiome modulation 2. There are only ~10–15 real global drug developers Unlike oncology, food allergy is still pre-commercial medicine. 3. Why Japan leads in Asia Japan has: strong vaccine technology regulatory support for pediatric immunotherapies large peanut allergy unmet need Quick Comparative Table Company Country Drug Phase MOA Trial ID Astellas Pharma Japan ASP0892 Phase 1–2 DNA allergy vaccine (immune tolerance) NCT03755713 Genome & Company South Korea GEN-001 / MTT Phase 2 Microbiome immune tolerance NCT05695261 Immunwork Taiwan Anti-IgE mAb Early clinical IgE neutralization (early stage regional trials) HK Regional biotech program Taiwan-linked Asia PPOIT Phase 2-type Oral immunotherapy + probiotic (controlled RCT) Important Context (Why the List Is Short) Food-allergy therapeutics is an unusually narrow drug class: Globally, >80% of the pipeline belongs to only 6 companies (Aimmune/Nestlé, DBV, Alladapt, Novartis, Regeneron, Cour Pharma). Asian companies have entered only recently (2016-2024). Therefore the above list actually represents most of the genuine Asian industry-sponsored development activity in the field today.

To know more about food allergy clinical trials, visit @ Food Allergy Treatment Drugs

Food Allergy Market Dynamics

Rising prevalence drives adoption of avoidance and epinephrine. Emerging therapies may reduce reactions and enable reintroduction of foods. Growth factors: Improved diagnostics and novel treatments. Challenges: Under-diagnosis in developing regions, economic burden, therapy failures, pricing issues, and lack of specialists.

Scope of the Food Allergy Market Report

Study Period: 2020-2034
Coverage: 7MM (US, EU-4, UK, Japan)
Key Companies: Vedanta Biosciences, Novartis, Alladapt, Regeneron, NIAID, Genentech, DBV Technologies, Aravax, ALK-Abello, Parexel, Allergy Therapeutics, others
Key Therapies: Vancomycin + VE416 with PNOIT, Ligelizumab, ADP101, Dupilumab, Omalizumab, DBV712, Remibrutinib, PVX-108, Peanut SLIT-tablet, VLP Peanut, others
Assessments: Marketed/emerging therapies, drug attributes, SWOT, entry strategies, unmet needs, KOL views, reimbursement.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

DelveInsight’s ‘Food Allergy–Epidemiology Forecast—2034’ report delivers an in-depth understanding of the Food Allergy, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), Japan, Canada and China. The leading Food Allergy Companies developing therapies include - Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc., Vedanta Biosciences, Inc., Regeneron Pharmaceuticals, Genentech, Inc., Rho Federal Systems Division, Inc., Alladapt Immunotherapeutics, Inc., Camallergy, and others.

Food Allergy- Pipeline Insight, 2026
DelveInsight’s, “Food Allergy- Pipeline Insight, 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Food Allergy pipeline landscape. The leading Food Allergy Companies developing therapies include - Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc., Vedanta Biosciences, Inc., Regeneron Pharmaceuticals, Genentech, Inc., Rho Federal Systems Division, Inc., Alladapt Immunotherapeutics, Inc., Camallergy, and others.